Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News 22nd PKPD Expertentreffen in the heart of the Black Forest 3rd GBHI in Amsterdam: lively discussions and intensive exchange with authorities Meet us in Amsterdam: 3rd GBHI Conference starts soon (12 – 13 April 2018) Meet us in Munich: AGAH Annual Meeting 26 – 27 April 2018 Regorafenib: first in human as eye drops 3rd GBHI conference – all speakers confirmed Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Centralised procedure Pharmacokinetics Audit Paediatricians Dermal irritation DDI Ocular tolerability CRA Drug Drug Interaction Xerostomia TTS Scientific advice Metered dose inhaler Patient recruitment SOP based Clinical pharmacology unit Sample size estimation Database Consultancy Scientific expertise WinNonlin Patch adhesion Good Clinical Practice Expert EMA Pharmacodynamic studies Protocol Phase III Slit lamp microscopy PASS Design development Monitoring Competence IVIVC Safety Allergy Subcontractor qualification Phase II GCP Statistical Analysis Plan Children Charcoal Oncology ICF US FDA Steady state Female adolescents Absorption Legal representative IEC FIM Biopharmaceutical OTC CDM MCID Phase I PAES Data management Project Management Experience Pilot study Statistical programming First in human Highly variable drugs Dry eye In vitro in vivo correlation Clinical development program DPI CDISC Inhalatives HRT Ophthalmological trials Creativity Biosimilars DUS Glaucoma AGAH Product development Bioequivalence Phase IV Patch Pulse oximetry plethysmography CRO Uveitis Lung Absorption windows Healthy subjects Clinical Monitoring Statistical services Phase IIb trials Pituitary Patients Phase IIa trials Transdermal therapeutic system ANVISA US CFR 21 Part 11 Quality Clinical study Anaesthesiologist Training Referral system Degeneration SocraTec C&S DFI Ophthalmologist Hormone replacement therapy Informed Consent Procedure MMM Legal Information Non interventional Eye disease Oncological patients IB Dry powder inhaler Local tolerability SAS Pragmatism Oncologic network Cardiovascular surveillance CDSIC Early phase Sensitisation trials Post authorisation Data Management Plan Cough Rhine Main area Pharmacokintetics Standardisation Life cycle management GCP training Investigators brochure Sequential designs Standard operating procedure Bioavailability Thuringia Contraception Ophthalmology Authorities Sore throat Hypothalamic ADAM Biometrics Drug Food Interaction Protocol development Spacious archive Phase I Unit Biopharmaceutics Axis Feasibility Intensive assessment station NIS CDASH Clinical trials MDI Dose linearity Inspection Recruitment rates FDA Quality Management System Ovulation inhibition Data Validation Plan Macular Elpro Adrenocortical COPD IMPD SDV CRF Auditing Common cold Copyright Immunogenicity Quality Assurance HPA axis Endpoint Central surveillance system Gynaecological trials HTA Efficacy Edema GLP Asthma Postmenopausal women Network Pharmacology Source Data Verification  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page